Online Program Home
My Program

Abstract Details

Activity Number: 525 - Clinical Trial Design- 6
Type: Contributed
Date/Time: Wednesday, August 1, 2018 : 10:30 AM to 12:20 PM
Sponsor: Biopharmaceutical Section
Abstract #328456
Title: How the ICH E9 Addendum Influenced a Phase III Clinical Trial with a Radiographic Endpoint
Author(s): Ruvie Martin*
Companies: Novartis Pharmaceuticals
Keywords: estimand; missing data; clinical trial; sensitivity analysis; radiographic

The ICH E9 (R1) Addendum on estimands and sensitivity analysis in clinical trials, promotes harmonised standards on the choice of estimand in clinical trials and describes an agreed framework for planning, conducting and interpreting sensitivity analyses of clinical trial data. It is intended to better align the choice of statistical methods with questions of regulatory importance and to improve the reliability of decisions about and representations of the effects of medical products. The draft addendum was released in August 2017 and is currently in a consultation period. Nevertheless, the addendum has already started to have an impact as new clinical trials have aligned with the principles outlined in the draft. To help build a knowledge bank that will aid the practical implementation of the addendum, sharing of experiences among statisticians is essential. With respect to this aim, here we will discuss a case study based on clinical trial with a radiographic endpoint. Different estimands, which were under consideration when designing the study, will be presented together with sensitivity analyses to answer the primary objective of the trial.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program